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Abstract
Background: Pneumococcal diseases remain a major cause of morbidity and mortality worldwide.
Updated data on drug-resistance from different populations may be important to recognize changes
in disease patterns. This study assessed current levels of penicilin resistance among Streptococcus
Pneumoniae causing pneumonia in Spanish middle age and older adults.
Methods: Antimicrobial susceptibility was tested for 104 consecutive isolates of Streptococcus
pneumoniae recovered from patients 50 years or older with radiographically confirmed pneumonia
in the region of Tarragona (Spain) between 2002 and 2007. According to the minimum inhibitory
concentration of tested antimicrobials (penicillin, erythromycin, cefotaxime and levofloxacin)
strains were classified as susceptible or resistant. Antimicrobial resistance was determined for early
cases (2002–2004) and contemporary cases (2005–2007).
Results:  Twenty-seven (25.9%) were penicillin-resistant strains (19 strains with intermediate
resistance and 8 strains with high resistance). Penicillin-resistance was higher in 2002–2004 than in
2005–2007 (39.5% vs 18.2%, p = 0.017).
Of 27 penicillin-resistant strains, 10 (37%) were resistant to erythromycin, 8 (29.6%) to cefotaxime,
2 (7.4%) to levofloxacin, and 4 (14.8%) were identified as multidrug resistant. Case-fatality rate was
higher among those patients who had an infection caused by any penicillin susceptible strain (16.9%)
than in those with infections due to penicillin-resistant strains.
Conclusion: Resistance to penicillin among Streptococcus pneumoniae remains high, but such
resistance does not result in increased mortality in patients with pneumococcal pneumonia.
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Background
Streptococcus pneumoniae is the most frequent isolate from
clinical samples of respiratory tract infection, including
acute exacerbations of chronic bronchitis and commu-
nity-acquired pneumonia [1-3]. The emergence of multi-
ple drug-resistance has complicated the empirical
treatment of pneumococcal infections. Several surveil-
lance programs that span numerous countries indicate
that the proportion of drug-resistant Streptococcus pneumo-
niae isolates continues to increase worldwide[4]. How-
ever, in Spain, where there was a great increase of
penicillin-resistance in 1980s, stabilization in 1990s and
a decrease in penicillin-resistant isolates in the last few
years has been reported [5-7].
In elderly people, the population group with highest rates
of pneumococcal infection, the penicillin intermediate-
susceptibility strains has not been associated with
increased mortality or unsuccessful treatments, so these
strains can be treated with β-lactams. If we consider peni-
cillin-resistant pneumococci, data reported on mortality
has not been uniform[4,8,9].
Updated data about drug-resistance in Streptococcus pneu-
moniae isolates from different populations may be impor-
tant in recognizing changes in disease patterns. The
present study describes current levels of drug resistance
among  Streptococcus pneumoniae causing community-
acquired pneumonia in Spanish middle aged and older
patients, and evaluates clinical factors associated with
increasing drug resistance or mortality.
Methods
Hospital case-series that included 104 consecutively
recruited isolates of Streptococcus pneumoniae recovered
from patients 50 years or older with a radiographycally
confirmed community-acquired pneumonia in the region
of Tarragona (a mixed residential industrial urban area in
the Northeast Mediterranean coast of Spain) with Antimi-
crobial susceptibility to penicillin tested between January
2002 and April 2007.
The isolates of S. pneumoniae were identified from blood
and sputum samples in the microbiology laboratory of
two reference hospitals in the study area (Joan XXIII and
Sant Pau i Santa Tecla) by standard methods. Pneumococ-
cal serotyping was carried out by the Quellung reaction
using the Statens Serum Institute (Copenhagen, Den-
mark) typing sera. Penicillin susceptibility was deter-
mined by the Kirby-Bauer disk diffusion method with a
disk containing 1 μg oxacillin (BD BBL, Sparks, MD USA).
Isolates were defined as resistant when the growth inhibi-
tion diameter was 19 mm or less. Minimal inhibitory con-
centration (MIC) for penicillin and cefotaxime was
determined by E-test method (AB Biodisk, Solna, Sweden)
following the manufacturer's instructions. Penicillin-sus-
ceptible was considered when MIC ≤ 0.06 μg/mL, penicil-
lin intermediate-resistant when MIC 0.12 – 1 μg/mL and
high resistance when MIC ≥ 2 μg/mL. Cefotaxime suscep-
tibility was considered when MIC ≤ 1 μg/mL, cefotaxime
intermediate when MIC 2 μg/mL and cefotaxime resistant
when MIC ≥ 4 μg/mL. Erythromycin and levofloxacin sus-
ceptibility was determined by the Kirby-Bauer disk diffu-
sion method with a disk containing 15 μg erythromycin
and 5 μg levofloxacin respectively (BD BBL, Sparks, MD
USA). Erythromycin susceptibility was considered when
the growth inhibition diameter was ≥ 21 mm, erythromy-
cin intermediate between 16 and 20 mm, and erythromy-
cin resistant ≤ 15 mm. Levofloxacin susceptibility was
considered when the growth inhibition diameter was ≥ 17
mm, levofloxacin intermediate between 14 and 16 mm,
and levofloxacin resistant ≤ 13 mm, according to the
guidelines established by the National Committee for
Clinical and Laboratory Standards (formerly NCCLS)[10].
Multidrug resistance was defined as intermediate resist-
ance or resistance to penicillin plus intermediate resist-
ance or resistance to ≥ 2 antimicrobial agents[11].
Cases were validated by checking clinical records and,
according to the presence of underlying medical condi-
tions, all patients were grouped into 3 risk strata on the
basis of the degree of immunocompromise and risk for
pneumococcal disease. High-risk level included persons
with conditions associated with possible immunocom-
promise: immunodeficiency (including AIDS), asplenia,
cancer (solid organ or haematological neoplasia), chronic
nephropathy (nephrotic syndrome, renal failure, dialysis
or transplantation), and long-term corticosteroid therapy
(20 mg/day of prednisone or equivalent). Moderate-risk
level included patients without a level 1 condition but
who had a history of chronic lung disease (chronic bron-
chitis, emphysema or asthma), liver disease (cirrhosis or
alcoholic hepatitis), heart disease (congestive heart failure
or chronic angina) and diabetes mellitus. Low-risk level
included patients without the above mentioned risk con-
ditions.
Pneumonia severity index (PSI) was calculated according
to criteria described in classical meta-analysis, and case-
fatality was considered when the patient died (in-hospital
or not) within the first 30 days after the diagnosis of pneu-
monia[12,13].
Penicillin-resistance was determined for early cases
(2002–2004) and contemporary cases (2005–2007). For
the statistical analysis, continuous variables were com-
pared by Student's t test, whereas categorical values were
compared using chi-squared or Fisher's test as appropri-
ate.BMC Infectious Diseases 2009, 9:36 http://www.biomedcentral.com/1471-2334/9/36
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The study was approved by the ethical committee of the
Catalan Health Institute and was conducted in accordance
with the general principles for observational studies set
out by this institution (Exp FIS 050231).
Results
Patient characteristics
Median age of case patients was 71.9 years (SD: 11.6), and
75 (72.1%) were male. Fifty-nine (56.7%) were 50–74
years-old, and 45 (43.3%) were 75 years or older. Five
cases were managed as outpatient and 99 were hospital-
ised (20 of which required admission to the ICU). Overall
case-fatality rate was 15.4% (40% among those admitted
in the ICU).
The most prevalent underlying conditions were chronic
pulmonary disease (33.7%), smoking (28.8%), chronic
hearth disease (25%) and diabetes mellitus (21.2%).
Thirty-one cases (29.8%) were assigned to high-risk level,
46 (44.2%) to moderate-risk level and 27 (26%) to low-
risk level. Twenty-five (24.1%) patients were assigned to
PSI classes' I-III and 79 (75.9%) to classes IV and V (table
1).
S. Pneumoniae serotypes
Pneumococcal serotype was identified in 60 cases,
whereas 14 cases were due to nonserotyped organisms
and 30 were not serotyped. Of the 60 serotyped cases, 12
(20%) were due to type 3, seven (11.7%) due to type 1,
four (6.7%) due to type 14, four (6.7%) due to type 6A,
four (6.7%) due to type 8, three (5%) due to type 6B, three
(5%) due to type 12F, two (3.3%) due to type 5, two
(3.3%) due to serotype 4, two (3.3%) due to type 19F, two
(3.3%) due to type 23A, two (3.3%) due to type 35B, two
(3.3%) due to type 7F, two (3.3%) due to type 19A, two
(3.3%) due to type 23B and one due to types 9V, 9N, 15B,
16, 23F, 33 and 38.
Antimicrobial susceptibility
Of the total 104 cases, 27 (25.9%) were penicillin-resist-
ant strains: 19 strains with intermediate resistance and 8
strains with high resistance (four cases with MIC = 2 μg/
mL; four cases with MIC = 4 μg/mL)
Of the 100 isolates tested for erythromycin, 19 (19%)
were resistant. For levofloxacin, 89 isolates were tested
and five (5.6%) were resistant. Among the 93 isolates
tested for cefotaxime, nine (9.7%) were resistant (table 2).
Table 1: Clinical characteristics of patients with pneumococcal pneumonia according to penicillin susceptibility.
Penicillin-Susceptible strains
N = 77
Penicillin-Resistant strains
N = 27
P-value* Overall Strains
N = 104
Age (yrs), mean (SD) 70.3 (11.8) 76.4 (9.5) 0.018 71.9 (11.6)
Sex:
Male 56 (72.7) 19 (70.4) 0.814 75 (72.1)
Female 21 (27.3) 8 (29.6) 29 (27.9)
Underlying conditions
Chronic pulmonary disease 26 (33.8) 9 (33.3) 0.967 35 (33.7)
Chronic hearth disease 18 (23.4) 8 (29.6) 0.519 26 (25)
Diabetes Mellitus 15 (19.5) 7 (25.9) 0.480 22 (21.2)
Stroke 5 (6.5) 2 (7.4) 0.870 7 (6.7)
Chronic liver disease 7 (9.1) 2 (7.4) 0.949 9 (8.7)
Chronic renal disease 10 (13.0) 7 (25.9) 0.118 17 (16.3)
Cancer 8 (10.4) 4 (14.8) 0.536 12 (11.5)
Alcoholism 11 (14.3) 0 (0) 0.038 11 (10.6)
Smoker 25 (32.5) 5 (18.5) 0.169 30 (28.8)
Corticosteroid therapy 3 (3.9) 3 (11.1) 0.166 6 (5.8)
Risk strata of patients
High 21 (27.2) 10 (37) 0.477 31 (29.8)
Moderate 36 (46.8) 10 (37) 0.516 46 (44.2)
Low 20 (26) 7 (25.9) 0.802 27 (26.0)
PSI classes
PSI I-III 18 (23.4) 7 (25.9) 0.790 25 (24.1)
PSI IV-V 59 (76.6) 20 (74.1) 79 (75.9)
NOTE: Data are numbers (percentage) of subjects, unless otherwise indicated. SD, standard deviation. PSI, pneumonia severity index.
* P-values were calculated by using Student's t test for continuous variables and chi-squared or Fisher's test for categorical variables, as appropriate.BMC Infectious Diseases 2009, 9:36 http://www.biomedcentral.com/1471-2334/9/36
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Only four (14.8%) isolates were identified as multidrug
resistant S. pneumoniae (MRSP). Of these, one case was
highly resistant to penicillin, cefotaxime and levofloxacin
and three cases were highly resistant to penicillin, erythro-
mycin and cefotaxime. Median age of patients with MRSP
was 76.8 years, all of them had an underlying disease (one
was current smoker, one had chronic heart disease and
two had a chronic pulmonary disease), three were non-
bacteremic cases and only one died. In three cases the
microorganism was resistant to the initial antimicrobial
regimen, and one of them died. Only two MRSP were
serotyped (6B both of them).
Globally, 76 specimens were recovered from blood sam-
ples and 28 from sputum samples. Of the 42 resistant
strains at least to one antibiotic, 26 (62%) were isolated
from blood and 16 (38.1%) were from sputum. Although
the difference did not reach statistical significance, peni-
cillin resistance was substantially higher among Streptococ-
cus pneumoniae recovered from sputum than from blood
(44.4% vs. 24.2%, p = 0.186).
Comparing penicillin-susceptible and non-susceptible
strains, statistically significant differences were observed
only for age (table 1). Of the 19 serotyped strains with
penicillin resistance, four (21.1%) were serotype 14, three
(15.8%) were serotype 23B, three (15.8%) were serotype
6B, two (10.5%) were serotype 19F, two (10.5%) were
serotype 6A, and one were serotypes 1, 3, 8, 9V and 35B.
Penicillin-resistance was substantially lower in contempo-
rary isolates than in early isolates (18.2% vs 39.5%, p =
0.017). Of the 38 early isolates, 10 strains with intermedi-
ate resistance and five strains with high resistance. Of the
66 contemporary strains, 9 strains with intermediate
resistance and three strains with high resistance. Among
patients 50–74 years old and among patients with moder-
ate risk this decrease was statistically significant (table 3).
Impact of resistance on severity outcomes
Mean length of hospital stay was slightly higher among
patients infected with penicillin-resistant strains than in
penicillin-susceptible strains (16.9 vs. 13.5 days; p =
Table 2: Antimicrobial resistance to cefotaxime, erythromycin and levofloxacin observed among pneumococcal strains isolated over 
the study period.
All isolates (N = 104) Penicillin resistant isolates (N = 27)
Tested Resistant strains Tested Resistant strains
Cefotaxime 93 9 (9.7) 27 8 (29.6)
Erythromycin 100 19 (19) 27 10 (37)
Levofloxacin 89 5 (5.6) 24 2 (8.3)
NOTE: Data are numbers (percentage) of strains.
Table 3: Comparison of patients with pneumococcal pneumonia caused by penicillin-resistant strains in early and contemporary 
isolates according to their age and risk stratum.
Early isolates
(2002–2004)
Contemporary isolates
(2005–2007)
Strata Overall strains Penicillin-resistant strains Overall strains Penicillin-resistant strains P-value*
Age
50–74 yrs 17 7(41.2) 42 2 (4.8) 0.001
75 yrs or more 21 8 (38.1) 24 10 (41.7) 0.807
Risk strata
High 11 4 (36.4) 20 6 (30) 0.717
Moderate 20 8 (40) 26 2 (7.7) 0.008
Low 7 3 (42.9) 20 4 (20) 0.235
Overall 38 15 (39.5) 66 12 (18.2) 0.017
NOTE: Data are numbers (percentage) of subjects.
* P-values were calculated by using Student's t test for continuous variables and chi-squared or Fisher's test for categorical variables, as appropriate.BMC Infectious Diseases 2009, 9:36 http://www.biomedcentral.com/1471-2334/9/36
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0.358). PSI score did not differ in both groups (112.5 vs.
111.1; p = 0.838).
Overall mortality was 15.4%. One patient died among the
8 cases with an inadequate initial antimicrobial therapy,
based on antibiogram results. Although it was not statisti-
cally significant, mortality was considerably higher
among those patients who had an infection caused by a
penicillin susceptible strain than in those with infections
due to penicillin-resistant strains (16.9% vs. 11.1%; p =
0.474).
Antimicrobial therapy
The antimicrobial therapies initially used in the 104
patients were: levofloxacin in 26 cases (25%), an associa-
tion of macrolide and cephalosporin in 18 cases (17.3%),
amoxicillin clavulanic acid in 14 cases (13.5%), a cepha-
losporin in 14 cases (13.5%), an association of macrolide
and amoxicillin clavulanic acid in 14 cases (13.5%) and
other treatments or associations in 18 cases (17.3%).
Considering the 8 cases classified as high-resistance to
penicillin, antimicrobial therapy initially used after CAP
diagnosis was levofloxacin in 3 cases, amoxicillin clavu-
lanic acid in two cases, an association of macrolide and
cephalosporin in two cases, and one case was treated with
tazobactam. One patient (a man 88 years-old, PSI class V,
treated with amoxicillin clavulanic acid, with bacteremic
pneumococcal pneumonia due to serotype 6B, resistant to
penicillin (MIC = 2) and resistant to cefotaxime, erythro-
mycin and clindamycin) died two days after hospital
admission, whereas the remaining 7 patients were non-
fatality cases.
Considering the 19 cases classified as intermediate-resist-
ance to penicillin, antimicrobial therapy initially used
after CAP diagnosis was cephalosporin in 5 cases, amoxi-
cillin clavulanic acid in 4 cases, an association of mac-
rolide and cephalosporin in 4 cases, levofloxacin in 2
cases, and other treatments or associations in 4 cases. Two
of these patients, both treated with a third generation
cephalosporin, died within 10 days after hospital admis-
sion (one case was a man 67 years old with bacteremic
pneumonia, PSI class V, due to serotype 14; and an other
case was a man 76 years-old with bacteremic pneumonia,
PSI class IV, due to serotype 6A), whereas the remaining
17 penicillin intermediate resistance cases were non-fatal-
ity cases.
Discussion
In the present study, the overall rate of penicillin-resist-
ance among isolates of Streptococcus pneumoniae was con-
siderable (25.9%). The proportion of penicillin-resistance
was higher among early isolates than in contemporary
isolates, which concurs with other Spanish stud-
ies[5,7,14]. Among Spanish individuals, Fenoll et al[7]
found that a high-level penicillin-resistance rate (MIC > 2
mg/l) decreased from 13.3% in 1997 to 12.9% in 2001. In
Catalonia, the high-level penicillin-resistance fell from
15% (1989–1993)[3] to 8.9% (1999–2002)[14], which
fits with the 9% found in our study. In contrast, the results
found in other countries showed an increase in penicillin-
resistance rate. In United States, the high-level penicillin-
resistance increased from 14.7% (1998–1999) to 18.4%
(2001–2002)[15]. Although several factors explain the
emergence of drug resistant Streptococcus pneumoniae, the
single most important consideration, however, is the
selective pressure of use of antimicrobial agents. Reduc-
tions in the rate of resistance found in our study could be
explain by a reduction in consumption of antibiotics in
Catalonia, going from 17.77 defined daily doses per 1000
inhabitants per day (DHD) in 1999 to 12.58 DHD in
2006, and could be partially attributed to the vaccination
that covers serotypes typically associated with drug resist-
ance[14].
We found a statistically higher age among patients
infected with penicillin-resistant strains than in those
infected with penicillin-susceptible strains. However,
because of low statistical power, we could not reject that
prevalence of underlying conditions was the predisposing
cause for this age-related differences in the aetiology of
pneumococcal pneumonia.
In accordance with previous studies[5,14] we found a
high proportion of underlying diseases among patients
with pneumococcal pneumonia. Although not statisti-
cally significant, the proportion of penicillin resistance in
our study was higher among patients with low or moder-
ate level risk in early isolates. Conversely, in contempo-
rary isolates this proportion was higher among patients in
high level of risk. Some studies[6,16] have reported that
patients with chronic pulmonary disease, HIV infected,
suspected aspiration or who were admitted to the hospital
within the previous 3 months were more likely than other
patients to have penicillin resistant pneumococcal pneu-
monia. In our study, only two patients had been hospital-
ized in prior 3 months, and none of them were HIV
infected. Chronic pulmonary disease was highly prevalent
in our study but differences were not observed in preva-
lence by penicillin resistance status.
Almost three quarter (74.1%) of penicillin-resistant pneu-
mococcal pneumonia were PSI classes IV-V. There was a
similar percentage of penicillin-resistant pneumonia
between PSI classes IV-V and PSI classes I-III. This results
agree with those found in other studies[6,16] that only
reported a trend for higher PSI classes to be associated
with penicillin-resistant pneumococcal pneumonia.BMC Infectious Diseases 2009, 9:36 http://www.biomedcentral.com/1471-2334/9/36
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In the present study, the rate of penicillin susceptibility
was higher in bacteremic than non-bacteremic cases
(65.8% vs. 42.9%). These fits with Aspa's report[6], where
penicillin susceptibility was 71% among blood culture
isolates and 50% among sputum isolates. In the USA, a
higher prevalence of resistance to penicillin among lower
respiratory tract than among isolates recovered from
blood samples (16.2% vs.  13.7%) has also been
reported[15].
In our study, most penicillin resistant S. pneumoniae iso-
lates were resistant to at least one additional antimicrobial
agent, and 3.8% (four cases) of all isolates were identified
as MRSP. As described in previous studies penicillin resist-
ance, particularly high-level resistance, predicts resistance
to other antimicrobials[11,14,17-19]. We found that all
MRSP were highly resistant to penicillin and cefotaxime,
and three of them were highly resistant to erythromycin
too.
We found that an inadequate initial antimicrobial treat-
ment was started in 7.7% of patients. Although in our
study there was no excess mortality due to initial inappro-
priate treatment (12.5%), likely due to a small sample
size, it is important to take into account underlying con-
dition or regional pattern of drug resistance for S. pneumo-
niae  in determining adequate antimicrobial
therapy[11,17,20].
In accordance with other studies[5,14,21,22], penicillin
resistance was not related with higher mortality. It has
been suggested that the primary determinant of virulence
might be the serotype rather than its sensitivity to penicil-
lin, and it is possible that the mechanisms conferring pen-
icillin resistance are related to those leading to a loss of
virulence. Previous studies of pneumococcal bacteremia
did not show differences in mortality between those with
susceptible and those with non-susceptible pneumococci
after adjustment for age, underlying disease, severity of ill-
ness on presentation, and appropriate concordant treat-
ment[5,6,16].
We found that three serotypes (14, 6B and 23B) were asso-
ciated with increasing risk of penicillin resistance,
accounting for a 53% of serotyped pneumococci causing
penicillin-resistant infections and the serotype 6B was
responsible for 50% of cases of MRSP. In accordance with
our results, Fenoll et al[7] reported that 56% of penicillin-
resistant pneumococcal strains belonged to serotypes 6
(18%), 14 (19%) and 19 (19%). In a long term follow-up
between 1983 and 2003 Mufson et al[23] found that all
blood isolates of penicillin-resistant were capsular sero-
types 6, 9, 14, 19 and 23.
Main limitation in this study includes the relatively low
number of cases and the difficulty to generalize results.
According to classical breakpoint criteria, it could be con-
cluded that, in the study area, resistance to penicillin
among Streptococcus pneumoniae remains high,
although such resistance does not result in increased
severity or mortality. However, it must be emphasized
that, according to the new breakpoint criteria for intrave-
nous penicillin[24], almost all strains in our study would
be susceptible.
To date, criteria for penicillin susceptibility of Streptococ-
cus pneumoniae remains unchanged for patients without
meningitis who can be treated with oral penicillin (e.g.,
for outpatient pneumonia). However, since 2008, for
patients without meningitis who are treated with intrave-
nous penicillin, the new breakpoints are ≤ 2, 4, and ≥ 8
μg/mL for susceptibility, intermediate-resistance and
high-resistance, respectively[24]. Thus, considering the
new pneumonia breakpoints, 100 (96.2%) of the 104
cases in our study would be penicillin-susceptible (MIC ≤
2  μg/mL), 4 (3.8%) would be penicillin intermediate-
resistant (MIC = 4 μg/mL) and none would be high resist-
ance (MIC ≥ 8 μg/mL).
According to the change in pneumonia breakpoint for
susceptibility[24], percentages of strains resistant to peni-
cillin have dramatically decreased worlwide. In Spain, a
large surveillance study that included 2,721 isolates of S.
Pneumoniae obtained from November 2001 to October
2002 in diferent Spanish Hospitals[25] reported that (tak-
ing into account the old pneumonia breakpoint) 20% of
overall strains were penicillin resistant (MIC >2 mg/mL)
and 24% were intermediate resistant strains (MIC = 0.12–
1 mg/mL). However, if we consider the new pneumonia
breakpoint, 94.3% of the total strains in the foremen-
tioned study would be currently considered penicillin sus-
ceptible, which is also in agreement with data found in
the present study (96.2% penicillin susceptible strains in
our study considering the new breakpoint).
Conclusion
According to classical pneumonia breakpoints for suscep-
tibility to penicillin, the resistance among Streptococcus
pneumoniae was considerable, but with the use of new
breakpoints, the percentage of Streptococcus pneumoniae
penicillin-resistant decreases dramatically.
In vitro penicillin resistance is not associated with increas-
ing mortality, even considering new breakpoints for sus-
ceptibility to intravenous penicillin.
The low mortality rates reported among patients with
pneumonia due to penicillin resistant strains could likely
be due to the fact that patients were treated with activePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:36 http://www.biomedcentral.com/1471-2334/9/36
Page 7 of 7
(page number not for citation purposes)
agents, such as penicillins or third generation cepha-
losporins.
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